Alnylam Pharmaceuticals Inc’s filing revealed that its Chief Executive Officer Greenstreet Yvonne unloaded Company’s shares for reported $1.31 million on Nov 26 ’24. In the deal valued at $250.98 per share,5,219 shares were sold. As a result of this transaction, Greenstreet Yvonne now holds 78,880 shares worth roughly $19.96 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Garg Pushkal sold 1,682 shares, generating $422,144 in total proceeds. Upon selling the shares at $250.98, the CMO & EVP Dev & Med Affairs now owns 17,457 shares.
Before that, Poulton Jeffrey V. sold 1,682 shares. Alnylam Pharmaceuticals Inc shares valued at $422,144 were divested by the EVP, Chief Financial Officer at a price of $250.98 per share. As a result of the transaction, Poulton Jeffrey V. now holds 30,644 shares, worth roughly $7.75 million.
Wolfe Research downgraded its Alnylam Pharmaceuticals Inc [ALNY] rating to an Underperform from a a Peer perform in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Goldman also remained covering ALNY and has increased its forecast on August 16, 2024 with a “Buy” recommendation from previously “Neutral” rating. Goldman revised its rating on February 16, 2024. It rated ALNY as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ALNY
On Monday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock fall -0.02% to $253.01. Over the last five days, the stock has gained 3.32%. Alnylam Pharmaceuticals Inc shares have risen nearly 32.18% since the year began. Nevertheless, the stocks have risen 50.38% over the past one year. While a 52-week high of $304.39 was reached on 10/17/24, a 52-week low of $141.98 was recorded on 04/25/24. SMA at 50 days reached $271.05, while 200 days put it at $214.53.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 251.58, which if violated will result in even more drops to 250.14. On the upside, there is a resistance level at 254.87. A further resistance level may holdings at 256.72. The Relative Strength Index (RSI) on the 14-day chart is 44.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.40, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 43.83%. Stochastics %K at 46.40% indicates the stock is a holding.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2024-11-15, dropping by -1.1 million shares to a total of 3.74 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 4.84 million shares. There was a decline of -29.48%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on February 15, 2024 when Wolfe Research began covering the stock and recommended ‘”a Peer perform”‘ rating .
